Yafei

Yafei (Shanghai) Biopharmaceutical Technology (also known as Yafei Biopharma or Affinity Biopharma) is a clinical-stage biopharmaceutical company focused on developing innovative anti-cancer therapeutics. The company utilizes its proprietary Tumor MicroEnvironment Activated (TMEA) platform to design smart small-molecule drug conjugates (SMDCs) and biologics that selectively release active payloads within the tumor microenvironment, thereby minimizing systemic toxicity and enhancing therapeutic efficacy. Its lead candidate, Legubicin (QHL-108), is a tumor-activated doxorubicin prodrug that has completed pivotal Phase II/III clinical trials for advanced soft tissue sarcoma, demonstrating significantly reduced cardiotoxicity and improved survival compared to conventional doxorubicin. Yafei's pipeline also includes other TMEA-based candidates such as IMD-1005 (a CD47-targeting antibody), IMD303 (an anti-CTLA-4 antibody), and IMD-101 (an IL-2 cytokine conjugate), targeting various solid tumors.